Liminatus Pharma Settles $8M Lawsuit by Issuing 4 Million Shares, Cancels Warrants

summarizeSummary

Liminatus Pharma settled a major legal dispute, including an $8 million default judgment, by issuing 4 million shares of common stock and cancelling warrants, removing a significant financial and legal risk.

check_boxKey Events · Legal and Risk Events · LIMN

• Settlement of Major Lawsuit

  Liminatus Pharma, Inc. entered into a settlement and release agreement with Clear Street LLC to resolve two pending legal actions, including a default judgment of $7.5 million plus approximately $515,000 in interest.

• Share Issuance for Settlement

  The company agreed to issue 4,000,000 shares of its common stock, valued at approximately $7.32 million, as consideration for the settlement.

• Warrant Cancellation

  In exchange for the shares, Clear Street LLC surrendered and cancelled 805,377 warrants to purchase common stock.

• Removes Significant Liability

  This settlement effectively removes an over $8 million default judgment and associated legal risks, which is a critical development for the company, especially given its recent delisting notice.

auto_awesomeAnalysis · LIMN · Life Sciences

Liminatus Pharma, Inc. has entered into a settlement agreement to resolve two significant legal actions, including a default judgment totaling over $8 million. The company will issue 4,000,000 shares of common stock, valued at approximately $7.32 million based on the current stock price, in exchange for the surrender and cancellation of 805,377 warrants. This move is critical for the company, especially following its recent Nasdaq delisting notice on January 26, 2026, for failing to maintain a minimum bid price. While the share issuance is substantially dilutive, it removes a major financial liability and legal overhang, which is paramount for a company facing delisting and financial distress. The market will likely weigh the significant dilution against the removal of a substantial debt burden and legal risk.